The US health regulator has provided its approval to Strides Shasun for potassium citrate extended release tablets which is used to prevent certain types of kidney stones.

Strides Shasun has said in a BSE filing that the company has received approval from the United States Food and Drug Administration (US FDA) for potassium citrate extended release tablets USP 5mEq, 10mEq and 15mEq.

The company has said that it is going to be the second generic player to commercialise the product and is going to launch it immediately.

Read EquityPandit’s Nifty Pharma Outlook for this week